Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocr - Wikidata - wikimedia - TriplyDB

Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocr

Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocr

http://www.wikidata.org/entity/Q37425156

about

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount Multiple Endocrine Neoplasia: Genetics and Clinical Management.Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.Pancreatic neuroendocrine tumor accompanied with multiple liver metastases.Continued rapid growth in (68) Ga applications: update 2013 to June 2014.Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice.The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever....

P2860

Q35675498-74DDAC76-A4D9-40D9-BCAF-0DC1C527DDEF Q36063577-945255DD-9320-4C27-B049-0DDAD82AB448 Q36128368-6A9B33F4-A486-43A5-A649-4488168A83B1 Q38251723-464764B8-A9C2-41E2-876F-0D29CA581367 Q38358666-0972C9FC-C1E0-46C6-B22B-AB35E4150C21 Q38612027-E25EFCD6-2C9A-4C79-90DD-74D419665977 Q47730141-B824B491-C457-4F6D-B72A-233778BFAECA Q48827044-687E5173-AECF-40D8-AB9F-DC344E3AD454

P2860

Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocr

http://www.wikidata.org/entity/Q37425156

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Does PRRT with standard activi ...... roenteropancreatic neuroendocr

@en

Does PRRT with standard activi ...... roenteropancreatic neuroendocr

@nl

type

label

Does PRRT with standard activi ...... roenteropancreatic neuroendocr

@en

Does PRRT with standard activi ...... roenteropancreatic neuroendocr

@nl

prefLabel

Does PRRT with standard activi ...... roenteropancreatic neuroendocr

@en

Does PRRT with standard activi ...... roenteropancreatic neuroendocr

@nl

P1433

Q37425156-AFAEED9F-56FF-4471-91AF-C23FFE503B11

P1476

Q37425156-843A4709-3E20-48E8-8862-4BEFE5D71F1E

P2093

Q37425156-05603813-B99F-4179-97AA-33EDB410563A

Q37425156-41F9992A-9943-471F-889F-DE17EF80957C

Q37425156-4EFD4596-21E3-4080-9F1F-86F71CC7F6D9

Q37425156-51A1CBA2-ACDC-4262-B6FB-C245B5AE9535

Q37425156-AE3B731C-B738-4763-869C-09C57AA1BBA0

Q37425156-EB8DF45C-5C5F-481C-B542-DB67F7E45D5F

P2860

Q37425156-0BB0A44C-B2F3-4CDC-8860-5C2A215F98EC

Q37425156-145D5209-78B5-4AE6-9F2E-3D2C359159D5

Q37425156-1CFD950F-2D91-4898-B478-29991DC3CB88

Q37425156-1F2EF495-2B3A-4B45-98BD-EB240EACFAF9

Q37425156-28ACA802-EAD4-46C5-89FC-4648427E877C

Q37425156-388899C3-BEED-4545-B010-F29EC519C303

Q37425156-50B721C0-6CCE-4799-9AD7-87F25940E374

Q37425156-53C8A4F4-C2F8-4773-8C62-AA727B1B2EEB

Q37425156-69338A29-5DA1-443A-B184-87D7615C0D46

Q37425156-6D44D22E-2C17-4B5A-8B9B-AE671E47454D

P2888

Q37425156-5BE07396-5233-4214-B703-9D908F4A9A43

P304

Q37425156-419DCF8E-BDB6-4D69-B4B1-C4E64A8952FA

P31

Q37425156-96DA28E5-982B-4B41-85D6-FD872BD0CD58

P356

Q37425156-1FE0B0D5-9215-44B5-9E46-93CF220BD69A

P433

Q37425156-BDA7CCC6-154D-479E-8E80-879E46872BCC

P478

Q37425156-ACD0993B-52F2-476B-9B4D-18DE1A44F021

P50

Q37425156-77601A6A-69C9-4B67-B4AE-87A31438608D

P577

Q37425156-367E2B22-F727-4E33-BAC0-DC4B2CA53012

P5875

Q37425156-CB71C177-9DBA-4451-B9B0-D62366A09014

P6179

Q37425156-B18349A7-AB4B-4EDF-AA3C-9C836788038F

P698

Q37425156-F0EC35CB-92A1-4809-9378-5C2309223A6F

P932

Q37425156-1DB3AECF-82A5-4D07-8463-C894AE33684A

P356

P1433

EJNMMI Research

P1476

Does PRRT with standard activi ...... ncreatic neuroendocrine tumors

@en

P2093

Ahmet Semih Dogan

http://www.w3.org/2001/XMLSchema#string

Amin Sabet

http://www.w3.org/2001/XMLSchema#string

Amir Sabet

http://www.w3.org/2001/XMLSchema#string

Hans-Jürgen Biersack

http://www.w3.org/2001/XMLSchema#string

Samer Ezziddin

http://www.w3.org/2001/XMLSchema#string

Stefan Guhlke

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.

Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Peptide receptors as molecular targets for cancer diagnosis and therapy.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

P2888

P304

82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2191-219X-3-82

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

James Nagarajah

P577

2013-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259468131

http://www.w3.org/2001/XMLSchema#string

P6179

1015398106

http://www.w3.org/2001/XMLSchema#string

P698

24369053

http://www.w3.org/2001/XMLSchema#string

P932

3877953

http://www.w3.org/2001/XMLSchema#string